Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

with some insurers reluctant to cover them simply for weight loss. In the 731-patient SUMMIT study, participants were randomly assigned to either tirzepatide at a dose of between 2.5mg and 15mg ...

This has saved hundreds of millions of lives since wide use of these “miracle drugs” started over 70 years ago. Loss of drug-effectiveness because of antimicrobial resistance (AMR) is increasing in ...